Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-26

Study Completion Date

2030-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiological Study on Malignancy Complicated With Renal Injury

NCT05392725

Kidney Injury

UNKNOWN

Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma

NCT05693012

Multiple Myeloma

UNKNOWN

Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria

NCT06469229

Hematuria Urothelial Carcinoma Bladder Cancer +2 more

NOT_YET_RECRUITING

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

NCT04883827

Renal Cell Carcinoma

COMPLETED

Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer

NCT00491621

Kidney Neoplasms

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Some studies have shown the potential of ctDNA in renal cancer monitoring, but the amount of ctDNA released in renal cancer is the lowest among non-cranial tumors. Even in advanced patients, the detection rate of tumor system mutation is less than 50%. DNA methylation is important in the process of tumor occurrence and development. However, no studies have focused on the value of ctDNA methylation in monitoring renal cancer, nor have large prospective cohort studies been conducted in patients with renal cancer.

This study intended to analyze the dynamic changes of circulating tumor DNA and its methylation status in patients with kidney cancer from preoperative to long-term follow-up, and to compare the evaluation value of methylation detection with traditional imaging examination and traditional blood tumor markers in the monitoring process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma Renal Cell Carcinoma RCC Kidney Neoplasms Kidney Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed renal cell carcinoma
* Without any treatment
* Agree and accept radical surgical treatment
* Signed written informed consent
* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1
* Follow up protocol and related procedures

Exclusion Criteria

* Had other cancers
* Had received any antitumor therapy before
* Known or suspected active autoimmune disease
* Informed consent is not possible due to medical or psychiatric problems
* Have clinical symptoms or diseases of the heart that are not well controlled
* Patients judged by the investigators to be unsuitable for inclusion in this study

Eligible Sex

ALL

Accepts Healthy Volunteers

No